Aurie has received U.S. Food and Drug Administration De Novo marketing authorization for the Aurie Reusable No-Touch Intermittent Catheter System, creating a new Class II device category for reusable intermittent urinary catheter systems. The authorization gives CathBuddy, Inc.’s medical device platform a regulatory pathway in a catheter market historically shaped by single-use products, with an initial commercial launch planned for Veterans Health Administration spinal cord injury hospitals later in 2026.
Why Aurie’s FDA De Novo authorization changes the regulatory path for reusable intermittent catheter systems
The significance of the Aurie FDA De Novo grant is not simply that one more catheter product has reached the U.S. market. The larger shift is that the U.S. Food and Drug Administration has now defined a regulated category for reusable intermittent urinary catheter systems, rather than treating reuse as an informal patient workaround or an unstructured cost-containment practice. That matters because intermittent catheterization sits at the difficult intersection of infection risk, long-term chronic use, patient independence, payer burden, and medical waste.
For decades, the commercial and clinical direction of intermittent catheterization has moved toward single-use devices, especially no-touch and hydrophilic formats designed to reduce contamination risk and simplify use. That model solved part of the safety problem, but it also created cost, supply, storage, and sustainability pressures for high-frequency users. Aurie’s authorization does not erase those trade-offs. It instead introduces a regulated alternative in which reuse is allowed only when the catheter is cleaned, high-level disinfected, and lubricated through the dedicated Aurie Personal Washer-Disinfector before use.
This distinction is central. Aurie is not asking clinicians or patients to accept improvised catheter reuse. The medical device manufacturer is attempting to convert reuse into a controlled, validated, prescription-device workflow. The opportunity is clear, but so is the burden. Any failure in adherence, reprocessing performance, labeling comprehension, device maintenance, or use-life tracking could weaken the clinical confidence needed for adoption.
What this reveals about FDA expectations for infection control and human factors in catheter reuse
The FDA’s classification order shows that infection control is likely to be the defining test for the reusable intermittent catheter category. Special controls include reprocessing validation of the catheter, validation of the microbicidal process, catheter performance testing, testing of reprocessing components, human factors testing, software verification, electrical safety testing, and labeling requirements. That is a demanding framework, and it signals that future entrants will need to prove more than mechanical catheter performance.
This matters because the core risk in intermittent catheterization is not only whether urine can be drained effectively. The real clinical question is whether repeated use can be managed without unacceptable contamination, user error, tissue reaction, urinary retention, pain, discomfort, or device malfunction. By placing human factors and validated directions for use at the center of special controls, the FDA appears to be treating the user workflow as part of the device’s safety profile.
That framing is commercially important. A reusable catheter system may appeal to payers and health systems if it reduces long-term expenditure on single-use supplies, but reimbursement and procurement committees will likely ask whether the operating model is simple enough for real-world use. The Aurie system includes a catheter intended for up to 100 uses, a portable washer-disinfector, and pre-packaged supply pods. The system design could reduce handling burden, but clinicians will still want evidence that users can follow the sequence correctly outside controlled environments.
Why the Veterans Health Administration launch may be a smart but demanding first market
Aurie’s planned initial launch through Veterans Health Administration spinal cord injury hospitals is strategically logical. Veterans with spinal cord injuries can represent a high-need population where intermittent catheterization may be frequent, long-term, and supply-intensive. A centralized hospital network also offers a more controlled early-adoption environment than a broad consumer launch, especially for a category where training, monitoring, and clinician confidence will matter.
That launch strategy may also help Aurie generate early real-world evidence in a setting with structured care pathways. For a new device category, adoption often depends not only on regulatory clearance but on whether clinicians can observe practical benefits in patient routines, infection-related outcomes, supply logistics, and total cost of care. The Veterans Health Administration setting could therefore become a proving ground for whether reusable catheter systems are scalable beyond the first authorized product.
However, the same setting also raises the bar. Spinal cord injury clinicians are likely to scrutinize urinary tract infection risk, device cleaning adherence, patient usability, and service support. A product positioned around sustainability and cost efficiency cannot succeed if frontline teams see it as adding training complexity or workflow uncertainty. Aurie’s early uptake will depend on whether the system feels like a clinical simplification rather than a clever engineering solution hunting for routine acceptance.
How Aurie could pressure single-use catheter economics without replacing the category overnight
The catheter market should not expect an instant flip from single-use to reusable systems. Single-use intermittent catheters have deep clinical familiarity, procurement channels, reimbursement patterns, and infection-control narratives behind them. Many clinicians may continue to prefer single-use devices for patients who face dexterity challenges, high infection risk, cognitive barriers, travel constraints, or limited access to cleaning supplies and device charging.
Even so, Aurie’s FDA De Novo authorization introduces a new competitive pressure point. If a reusable system can deliver no-touch catheter features at a lower recurring cost, payers and integrated health systems may start asking harder questions about whether all intermittent catheter users need single-use products in every setting. That does not mean single-use catheters lose relevance. It means the economics of chronic catheter supply could become more segmented.
The most likely near-term market impact is targeted adoption among users and institutions where frequency, cost, logistics, and sustainability make reuse particularly compelling. The more difficult question is whether reusable catheter systems can establish clinical trust across broader home-care environments. That will require patient education, durable device support, supply pod availability, service reliability, and evidence that real-world use matches the validated conditions reviewed by regulators.
Why leadership additions suggest Aurie is preparing for commercialization rather than just clearance
Aurie’s leadership moves also point to a transition from regulatory milestone to commercial execution. The appointment of Manu Varma as an independent board director brings chronic care and intermittent catheter market experience into governance at a crucial stage. Dr. Christopher Elliott’s addition to the Scientific Advisory Board adds clinical credibility in a field where sustainable alternatives to single-use catheters remain a sensitive subject. Sergey Grigoryants’ promotion to Chief Technology Officer suggests the technology roadmap will remain central to Aurie’s positioning, particularly with plans involving infection-detecting sensor-enabled catheters.
The challenge is that commercialization of a novel device category is rarely solved by regulatory clearance alone. Aurie must now operate like a device company, a service-support organization, and a behavior-change platform at the same time. The medical device manufacturer will need to convince clinicians that the reprocessing workflow is reliable, persuade users that the system is practical, and satisfy payers that the economics justify adoption.
That is a tougher job than selling a conventional catheter SKU. The reusable system includes hardware, disposables, instructions, maintenance, use-life limits, and potentially future digital or sensor-enabled features. Each additional component can increase value, but it can also introduce friction. The strongest commercial path will likely be one where Aurie proves that automation reduces complexity rather than adding another layer to an already sensitive daily care routine.
What clinicians, regulators, and medtech observers will watch after the Aurie launch
The next phase for Aurie will be judged through evidence, not novelty. Clinicians will watch whether the system performs reliably in daily use, how patients handle the cleaning and disinfection process, and whether infection-related concerns remain controlled outside formal testing. Regulators will watch adverse event reporting, labeling effectiveness, device maintenance, and whether the new classification supports safe follow-on innovation.
Industry observers will also track whether the De Novo decision encourages other medtech developers to build reusable or reprocessable products in categories long dominated by single-use devices. If Aurie succeeds, the precedent could extend beyond intermittent catheterization and influence how device makers frame sustainability, affordability, and infection control in chronic-care consumables. If uptake is slow, the lesson may be that regulatory authorization can open a category, but behavioral adoption still determines whether the category becomes commercially meaningful.
For now, Aurie has achieved something genuinely new in a mature device segment. The FDA De Novo grant creates a formal pathway for reusable intermittent catheter systems, but the market test starts now. The central question is whether hospitals, clinicians, payers, and patients will view controlled reuse as a credible improvement over single-use convenience, or as a promising idea that still has to prove it can survive the messy realities of home-based chronic care.
